MediGene Pads Coffers, Inks $17.7M Eligard Royalty Deal
MediGene AG became the latest biotech to choose a royalty deal over other financing options to bolster its bottom line. Last week, the company transferred its 2 percent royalty share of European net sales in prostate cancer drug Eligard (leuprolide acetate) to Cowen Healthcare Royalty Partners II LP for $17.7 million in cash.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter